On September 21, 2026 Kian Immune Cell Co. reported that it hosted a lively scientific discussion that brought together researchers, students, and colleagues for an exchange the company describes as genuine scientific thinking in action.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Zohreh Mirlavasani shared insights on dendritic cell (DC) vaccines and explored how artificial intelligence could improve their development and therapeutic efficacy. Students and colleagues from the Royan Cancer Stem Cell Group engaged actively throughout the session, raising thoughtful questions and driving a wide-ranging scientific brainstorm.

The discussion converged on one of the most compelling questions in cancer immunotherapy today: which holds greater potential for treating cancer — mRNA vaccines or DC vaccines? No simple answer emerged, and the conversation reflected the depth and fast-evolving nature of the field. Kian Immune Cell Co. looks forward to continuing this dialogue and invites the broader scientific community to share their perspectives.

(Press release, Kian Immune Cell, SEP 21, 2026, View Source [SID1234670970])